This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miao, X. Articles by Lin, D. Search for Related Content PubMed PubMed Citation Articles by Miao, X. Articles by Lin, D.

A Functional Polymorphism in the Matrix Metalloproteinase-2 Gene Promoter (-1306C/T) Is Associated with Risk of Development but not Metastasis of Gastric Cardia Adenocarcinoma¹

Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Matrix metalloproteinase-2 (MMP-2) has been shown to play an importantrole in multiple ways to all stages of cancer initiation and development.We have reported previously a strong association between a functional single nucleotide polymorphism (–1306C/T) in the MMP2 promoter and risk of lung cancer (C. Yu et al., Cancer Res., 62: 6430–6433, 2002). This case control study was to assess the contribution of this MMP2 polymorphism to risk of development and metastasis of gastric cardia adenocarcinoma (GCA). MMP2 genotypes were determined by PCR-based denaturing high-performance liquid chromatography analysis and direct DNA sequencing in 356 patients with GCA and 789 frequency-matched controls in an ethnic Chinese population. We found that subjects with the CC genotype had >3-fold increased risk [adjusted odds ratio 3.36, 95% confidence interval 2.34–4.97] for developing GCA compared with those with the variant CT or TT genotype. Furthermore, the increased risk was found to be more pronounced in smokers and younger subjects. However, no significant association was demonstrated between the MMP2 polymorphism and risk of metastasis of the cancer at the time of diagnosis, with the odds ratio being 0.90 (95% confidence interval 0.36–2.20) for the CC genotype. These findings are consistent with our initial observation for lung cancer and further support the hypothesis that MMP2 genotype may influence individual susceptibility to the development of certain cancer.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The MMPs⁴ are a large family of proteolytic enzymes that consist of >20 members. These proteolytic enzymes are present in normal healthy individuals and up-regulated in almost every type of human cancers (reviewed in Ref. 1 ). Historically, MMPs were considered to play an important role in cancer invasion and metastasis because of their features capable of degrading extracellular matrix and basement membrane barriers (2 , 3) . However, recent studies have demonstrated that MMPs are also involved in several steps of cancer development by modulating cell proliferation, apoptosis, and host immune surveillance (reviewed in Ref. 1 ). MMP-2, among other MMPs, primarily hydrolyzes type IV collagen, the major structural component of basement membrane (3 , 4) . This proteinase also has high activity toward many other bioactive molecules, such as growth factor-binding proteins and growth factor receptors (reviewed in Ref. 1 ), e.g., MMP-2 can cleave insulin-like growth factor-binding proteins and release insulin-like growth factors, which are well known to have a strong effect on stimulating cell proliferation and inhibiting apoptosis. These activities of MMP-2 are believed to be linked to both cancer development and progression.

In contrast to the majority of MMPs, MMP-2 is constitutively expressed by a large number of cell types and overexpressed in a wide variety of human cancer, including gastroesophageal cancer (5, 6, 7, 8) . Although the activity of MMP-2 is known to be regulated by post-transcriptional mechanisms, including the activation of proenzyme and inhibition of enzyme activity (1 , 4) , transcriptional regulation is also believed to be pivotally important because the human MMP2 promoter contains a number of cis-acting regulatory elements, and several transcription factors, including p53, Sp1, Sp3, and AP-2, participate in the control of its constitutive expression (9 , 10) . Recently, Price et al. (11) reported a single nucleotide polymorphism in the promoter of the MMP2 gene (-1306C/T). The -1306CT transition is located in a core recognition sequence of Sp1 (CCACC box), which abolishes the Sp1-binding site and consequently diminishes promoter activity. Transient transfection experiments showed that reporter gene expression driven by the C allelic MMP2 promoter was significantly greater than reporter gene expression driven by the T allelic counterpart both in epithelial cells and macrophages, indicating the functional significance of this polymorphism (11) .

The cancers in which an effect for MMP-2 has been established are characterized by varying individual susceptibility, implying the role of genetic factors. However, like many MMPs, MMP-2 is not up-regulated by gene amplification or activating mutations, and genetic alternations in the gene of the cancer cells are generally lacking. Therefore, germ-line polymorphisms that alter constitutive and/or induced expression and enzyme activity of MMP-2 may affect individual susceptibility to certain cancers. It has been hypothesized that the MMP2 -1306C alleles might render increased risk for carcinogenesis because of an elevated level of MMP-2 expression over a lifetime. We have recently shown in a molecular epidemiological study that the frequency of the MMP2 -1306CC genotype was significantly higher in patients with lung cancer than in the healthy population, and this genotype was associated with several folds of increased risk of lung cancer solely or in a manner of interaction with smoking exposure (12) . The present report described a case control study that aimed to test the hypothesis in GCA. In addition, we also assessed the contribution of the MMP2 polymorphism to risk of metastasis of the cancer.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Study Subjects.
This study consisted of 356 patients with GCA and 789 healthy controls, and all subjects were ethnic Chinese. Patients were consecutively recruited from January 1997 to July 2002, at the Cancer Hospital, Chinese Academy of Medical Sciences (Beijing). In this study, GCA was defined as tumors arising at the gastric cardia and/or gastroesophageal junction with or without involvement of other esophageal and/or gastric subsites. Tumors confined entirely to the esophageal or gastric subsites were excluded. All patients with histopathologically confirmed GCA were enrolled, yielding a 94% response rate. Because this was a study of genotype and the marker was a constitutional one, both incident and prevalent cases were included. A portion of cases (217) was participants in a molecular epidemiological study of MTHFR and GCA as reported previously (13) . Of the 356 patients, 275 (77.2%) underwent surgical resection and had detailed metastatic data. The presence (M+) or absence of detectable metastases (M-) were evaluated according to the Tumor-Node-Metastasis classification (14) on the basis of the postoperative histophathological examination. Population controls were cancer-free individuals living in Beijing region; they were selected from a community cancer screening program for early detection of cancer conducted during the same period as the cases were collected (13) . Briefly, these controls were randomly selected from a pool of 2800 individuals based on a physical examination, and the response rate was 96%. The selection criteria included no individual history of cancer, and frequency matched to GCA cases on sex and age (±5 years). At recruitment, informed consent was obtained from each subject, and each participant was then interviewed to solicit detailed information on demographic characteristics and lifetime history of tobacco use. This study was approved by the Institutional Review Board of the Chinese Academy of Medical Sciences Cancer Institute.

MMP-2 Genotyping.
Genomic DNA was isolated from peripheral blood of the controls and most of the cases. Approximately 30% of DNA samples from cases were isolated from surgically resected "normal" tissues adjacent to the tumor of GCA patients. MMP2 genotyping was accomplished by PCR-based DHPLC analysis and direct DNA sequencing as reported previously (12) . The primers used to amplify a 295-bp fragment of MMP2 promoter containing –1306 C/T site were: MMP-2F, 5'-CTG ACC CCC AGT CCT ATC TGC C and MMP-2R, 5'-TGT TGG GAA CGC CTG ACT TCA G. PCR was accomplished with a 25-µl reaction mixture containing 100 ng of DNA, 1 µM each primer, 0.2 mM deoxynucleotide triphosphate, 2 mM MgCl₂, 1 unit of Taq DNA polymerase with 1 x reaction buffer (Promega, Madison, WI), and 2% DMSO. The PCR profile consisted of an initial melting step of 2 min at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 64°C, and 45 s at 72°C, and a final elongation of 7 min at 72°C. DHPLC analysis was performed on a Transgenomic WAVE System (Transgenomic, Inc., Omaha, NE). The detailed genotyping process was described in our recent publication (12) . Briefly, each PCR product was denatured for 1 min at 94°C and then gradually reannealed by decreasing sample temperature from 94°C to 45°C over a period of 30 min to form homo- and/or hetero-duplexes. The PCR products were then applied to the DHPLC column and eluted with a linear acetonitrile gradient at a flow rate of 0.9 ml/min. The genotypes of MMP2 –1306 C/T revealed by DHPLC analysis were further confirmed by DNA sequencing. To ensure quality control, genotyping was performed with blinding to case control status, and a 10% random sample of cases and controls was genotyped twice by different persons; the reproducibility was 100%.

Statistical Analysis.
Pearson’s ² test was used to examine differences in demographic variables, smoking, and distributions of genotypes between cases and controls and metastatic and nonmetastatic cases. The associations between the MMP2 polymorphism and risk of development and metastasis of GCA were estimated by ORs and their 95% CIs, which were calculated by unconditional logistic regression models. Smokers were considered current smokers if they smoked 1 year before the date of diagnosis for cases or up to the date of the interview for controls. Information was collected on the amount of cigarettes smoked per day, the age at which the subjects started smoking, and the age at which ex-smokers stopped smoking. Light or heavy smokers were categorized by the 50th percentile pack-year value among controls, i.e., <26 or 26 pack-years [(cigarettes per day ÷ 20) x (years smoked)]. Because only 15 cases and 27 controls were ex-smokers, they were combined with current smokers for analysis. The ORs were adjusted for age, sex, and pack-years smoked. All analysis was carried out with Statistical Analysis System software (Version 6.12; SAS Institute, Cary, NC).

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The relevant characteristics of the study subjects are shown in Table 1 . The age and gender distributions among cases and controls were not statistically different. The median age was 58.4 years (range 41–72) for the case group and 57.6 years (range 45–76) for the control group. More smokers were presented in cases compared with controls (55.9 versus 48.8%; P < 0.05), and the mean duration of smoking among cases was significantly longer than among controls (15.5 versus 13.2 years; P < 0.05). However, the distribution in lighter (<26 pack-years) and heavier smokers (26 pack-years) between cases and controls was not significantly different (P = 0.97).

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
In the previous study, we have reported that the -1306C/T polymorphism in the promoter of MMP2 is a strong genetic susceptibility factor for lung cancer, and the CC genotype confers several-fold increased risk for developing the cancer (12) . Because MMP-2 has been shown to be overexpressed in gastroesophageal cancer and appears to be a feature of the malignant phenotype (7 , 8 , 15) , we therefore examined whether the functional polymorphism in the MMP2 promoter could have some impact on the risk of GCA development and metastasis. On the basis of analysis with 356 cases with GCA and 789 controls, we found that subjects carrying the CC genotype had a >3-fold increased risk for developing GCA, whereas no effect of this polymorphism on metastasis of the cancer was observed. These results are consistent with our previous findings from the lung cancer study (12) and further support the hypothesis that the MMP2 -1306CC genotype may constitute a common susceptibility factor for certain cancers.

Our molecular epidemiological results are parallel to the laboratory findings showing that the –1306CT transition in the promoter region of MMP2, which disrupts an Sp1-binding site (CCACC box), leads to a strikingly lower promoter activity with the T allele (11) . Deletion or site-directed mutagenesis analysis of MMP2 promoter has also shown that the Sp1 site, among other promoter elements such as AP-2, is critical for constitutive activity of this gene (10) . On the other hand, recent study also demonstrated that reduction of Sp1 DNA-binding activity or phosphorylation by nonsteroidal anti-inflammatory drugs suppresses MMP2 expression (16) . Taken together, these data clearly suggest that the presence of Sp1 consensus sequence in the MMP2 –1306C allele may enhance transcription, which in turn would produce higher levels of MMP-2 protein in individuals carrying the CC genotype than those carrying the TT or CT genotype. Because MMP-2 plays an important role in multiple ways to all stages of cancer initiation and development (see above), one would expect that individuals who carry the CC genotype and therefore have increased expression of this enzyme over a lifetime may be more susceptible to cancer. The association between high levels of constitutive expression of MMP-2 and susceptibility to tumor formation has been tested in several studies with genetically modified animals. It was found that when induced by carcinogenic stimulus, mice that lack the Mmp2 or Mmp9 gene developed fewer tumors than wild-type mice (17) . Cancer cells injected via vein were found to be less capable of colonizing the lungs of Mmp2-knockout mice than lungs of wild-type mice (18) . Conversely, transgenic mice that overexpress membrane type-MMP-1, a known activator of pro-MMP-2, were at increased susceptibility to mammary tumor formation and metastasis (19) . These data strongly support our epidemiological observation that the genetic polymorphism resulting in high expression of MMP-2 over a lifetime may increase cancer susceptibility. In addition, functional polymorphisms in some other MMP genes have also been reported to be associated with risk of certain cancers, e.g., a single guanine insertion polymorphism in the MMP1 promoter region, which creates an Ets-binding site and enhances transcriptional activity, has been associated with increased risk for lung (20) , colorectal (21 , 22) , endometrial (23) , and ovarian cancer (24) . A single adenosine insertion polymorphism in the MMP3 promoter (6A allele), which has half the transcriptional activity of the 5A allele, has been linked to reduced susceptibility to breast cancer (25) .

In this study, we found that the association between the MMP2 –1306CC genotype and GCA risk appeared to be more pronounced in younger subjects (<60 years old). This finding is in line with the conception that genetic susceptibility is often associated with an early age of disease onset. We also found a significantly higher risk for GCA related to the MMP2 –1306CC genotype among smokers and smokers who smoked 26 pack-years. Because the expression of MMPs can be induced by smoking (26 , 27) , one suggestive explanation of these findings is that, in addition to higher constitutive expression attributable to gain of an Sp1 promoter site, the inducibility by smoking of the C allele of MMP2 may also be higher than that of the T allele, which loses an Sp1 site. Given these conditions, it would be expected that smokers, especially heavy smokers, who carried the CC genotype were at the highest risk. Numerous studies have consistently shown that tobacco smoke may play an important role as an environmental etiological factor in the development of GCA (28, 29, 30, 31) . Therefore, another explanation for a higher risk of GCA among smokers and heavy smokers with the CC genotype could be that these subjects had larger numbers of transformed cells caused by tobacco carcinogens in the target tissue, which consequently increases the possibility that one of these cells will form malignancy under the condition of higher MMP2 expression.

Local overexpression of MMP-2 has been shown to be correlated to invasion and metastasis of certain cancers, including gastroesophageal cancers (15 , 32 , 33) . Several studies have suggested that genetic polymorphism in the promoter of MMP1 (1G/2G) or MMP3 (5A/6A), which alters the transcription activity of the genes, may influence invasiveness or metastasis of some types of cancer, such as melanoma (34) , colorectal cancer (21) , and breast cancer (25) . In the present study, we did not find any significant association between MMP2 genotype and status of lymph node metastasis of GCA, questioning the major role of the CC genotype as a relevant genetic factor inducing the local overexpression of MMP-2 and as a risk marker of metastatic disease. However, these data on metastasis should be considered as preliminary data because of limited sample size and metastatic parameter. Additional examinations of larger patient series with more detailed clinicopathological features and clinic outcome, especially the survival rate, may be required.

Our study may have certain limitations because of the study design. Because it was a hospital-based, case control study and the cases were from the hospital and the controls were from the community, selection bias and/or systematic error may occur. It would therefore be important to confirm these findings in a population-based prospective study. In addition, excepting for tobacco smoking, other factors, such as gastroesophageal reflux disease, obesity, and certain dietary components, are known to be associated with risk of GCA (35 , 36) . These factors might interact with MMP2 genotype or act as potential confounders in the analysis. Unfortunately, information on these factors in our case control study is not available. It would be interesting to investigate the interaction between MMP2 genotype and these risk factors, especially gastroesophageal reflux disease on risk of GCA in additional studies.

In conclusion, our study provides the first evidence that the MMP2 -1306C/T polymorphism is a genetic susceptibility factor for the development of GCA, with the CC genotype being associated with increased risk of the cancer in Chinese population. This association is especially noteworthy in younger individuals and smokers. These results are consistent with our previous findings in the lung cancer study, further supporting the hypothesis that MMP-2 may play an important role in carcinogenesis. The MMP2 genotype seems not associated with the risk for metastatic of GCA, although additional studies are needed to clarify this important issue.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by Grants 39825122 and 39990570 from National Natural Science Foundation and Grant G1998051204 from State Key Basic Research Program.

² X. M. and C. Y. contributed equally to this work.

³ To whom requests for reprints should be addressed, at Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021, China. Phone: 86-10-677-22460; Fax: 86-10-677-13359; E-mail: dlin{at}public.bta.net.cn

⁴ The abbreviations used are: MMP, matrix metalloproteinase; DHPLC, denaturing high-performance liquid chromatography; OR, odds ratio; CI, confidence interval; GCA, gastric cardia adenocarcinoma.

Received 3/ 6/03. Accepted 5/ 2/03.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2: 161-174, 2002.[Medline]
2. Curran S., Murray G. I. Matrix metallproteinases in tumor invasion and metastasis. J. Pathol., 189: 300-308, 1999.[Medline]
3. Stamenkovic I. Matrix metallproteinases in tumor invasion and metastasis. Semin. Cancer Biol., 10: 415-433, 2000.[Medline]
4. Nagase H., Woessner J. F., Jr. Matrix metalloproteinase. J. Biol. Chem., 274: 21491-21494, 1999.[Free Full Text]
5. Boag A. H., Young I. D. Increased expression of the 72 Kda type IV collagenase in prostatic adenocarcinoma. Am. J. Pathol., 144: 585-591, 1994.[Abstract]
6. Galateau-Salle F. B., Luna R. E., Horiba K., Sheppard M. N., Hayashi T., Fleming M. V., Colby T. V., Bennett W., Harris C. C., Stetler-Stevenson W. G., Liotta L., Ferrans V. J., Travis W. D. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum. Pathol., 31: 296-305, 2000.[Medline]
7. Murray G. I., Duncan M. E., Arbuckle E., Melvin W. T., Fothergill J. E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 43: 791-797, 1998.[Abstract/Free Full Text]
8. Parsons S. L., Watson S. A., Collins H. M., Griffin N. R., Clarke P. A., Steele R. J. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br. J. Cancer, 78: 1495-1502, 1998.[Medline]
9. Bian J., Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol., 17: 6330-6338, 1997.[Abstract]
10. Qin H., Sun Y., Benveniste E. N. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem., 274: 29130-29137, 1999.[Abstract/Free Full Text]
11. Price S. J., Greaves D. R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem., 276: 7549-7558, 2001.[Abstract/Free Full Text]
12. Yu C., Pan K., Xing D., Liang G., Tan W., Zhang L., Lin D. Correlation between a single nucleotide polymorphism in the Matrix Metalloproteinase-2 promoter and risk of lung cancer. Cancer Res., 62: 6430-6433, 2002.[Abstract/Free Full Text]
13. Miao X., Xing D., Tan W., Qi J., Lu W., Lin D. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population. Cancer Epidemiol. Biomark. Prev., 11: 1454-1458, 2002.[Abstract/Free Full Text]
14. Sobin L. H. Wittekind C. eds. . TNM Classification of Malignant Tumors, Ed. 5. Wiley-Leiss New York 1997.
15. Koyama H., Iwata H., Kuwabara Y., Iwase H., Kobayashi S., Fujii Y. Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur. J. Cancer, 36: 2164-2170, 2000.
16. Pan M-R., Hung W-C. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. Proc. Natl. Acad. Sci. USA, 277: 32775-32780, 2002.
17. Bergers G., Brekken R., Mcmahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorp P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2: 737-744, 2000.[Medline]
18. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogeneisis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.[Abstract/Free Full Text]
19. Ha H. Y., Moon H. B., Nam M. S., Lee J. W., Ryoo Z. Y., Lee T. H., Lee K. K., So B. J., Sato H., Seiki M., Yu D. Y. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res., 61: 984-990, 2001.[Abstract/Free Full Text]
20. Zhu Y., Spitz M. R., Lei L., Mills G. B., Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhance lung cancer susceptibility. Cancer Res., 61: 7825-7829, 2001.[Abstract/Free Full Text]
21. Ghilardi G., Biondi M. L., Mangoni J., Leviti S., DeMonti M., Guagnellini E., Scorza R. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin. Cancer Res., 7: 2344-2346, 2001.[Abstract/Free Full Text]
22. Hinoda Y., Okayama N., Takano N., Fujimura K., Suehiro Y., Hamanaka Y., Hazama S., Kitamura Y., Kamatani N., Oka M. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 gene with colorectal cancer. Int. J. Cancer, 102: 526-529, 2002.[Medline]
23. Nishioka Y., Kobayashi K., Sagae S., Ishioka S., Nishikawa A., Matsushima M., Kanamori Y., Minaguchi T., Nakamura Y., Tokino T., Kudo R. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn. J. Cancer Res., 91: 612-615, 2000.[Medline]
24. Kanamori Y., Matsushima M., Minaguchi T., Kobayashi K., Sagae S., Kudo R., Terakawa N., Nakamura Y. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancer and insertion/deletion polymorphism in its promoter region. Cancer Res., 59: 4225-4227, 1999.[Abstract/Free Full Text]
25. Ghilardi G., Biondi M. L., Caputo M., Leviti S., DeMonti M., Guagnellini E., Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res., 8: 3820-3823, 2002.[Abstract/Free Full Text]
26. Lahman C., Bergemann J., Harrison G., Young A. R. Matrix metalloproteinase-1 and skin aging in smokers. Lancet, 357: 935-936, 2001.[Medline]
27. Russell R. E., Culpitt S. V., DeMatos C., Donnelly L., Smith M., Wiggins J., Barnes P. J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol., 26: 602-609, 2002.[Abstract/Free Full Text]
28. Gammon M. D., Schoenberg J. B., Ahsan H., Risch H. A., Vaughan T. L., Chow W. H., Rotterdam H., West A. B., Dubrow R., Stanford J. L., Mayne S. T., Farrow D. C., Niwa S., Blot W. J., Fraumeni J. F., Jr. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. (Bethesda), 89: 1277-1284, 1997.[Abstract/Free Full Text]
29. Ji B. T., Chow W. H., Yang G., McLaughlin J. K., Gao R. N., Zheng W., Shu X. O., Jin F., Fraumeni J. F., Jr., Gao Y. T. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer, 77: 2449-2457, 1997.
30. Wu A. H., Wan P., Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of stomach and esophagus (United States). Cancer Causes Control, 12: 721-732, 2001.[Medline]
31. Mao Y., Hu J., Semenciw R., White K., Canadian Cancer Registries Epidemiology Research Group. Active and passive smoking and the risk of stomach cancer, by subsite, in Canada. Eur. J. Cancer Prev., 11: 27-38, 2002.[Medline]
32. Monig S. P., Baldus S. E., Hennecken J. K., Spiecker D. B., Grass G., Schneider P. M., Thiele J., Dienes H. P., Holscher A. H. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology, 39: 597-602, 2001.[Medline]
33. Nomura H., Fujimoto N., Seiki M., Mai M., Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer, 69: 9-16, 1996.[Medline]
34. Ye S., Dhillon S., Turner S. J., Bateman A. C., Theaker J. M., Pickering R. M., Day I., Howell W. M. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res., 61: 1296-1298, 2001.[Abstract/Free Full Text]
35. Mayne S. T., Navarro S. A. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J. Nutr., 132(Suppl.11): 3467s-3470s, 2002.
36. Ji B. T., Chow W. H., Yang G., Mclaughlin J. K., Gao R. N., Zheng W., Shu X. O., Jin F., Fraumeni J. F., Jr., Gao Y. T. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol. Biomark. Prev., 6: 481-485, 1997.[Abstract]

This article has been cited by other articles:

				J. V. Cockle, N. Gopichandran, J. J. Walker, M. I. Levene, and N. M. Orsi Matrix Metalloproteinases and Their Tissue Inhibitors in Preterm Perinatal Complications Reproductive Sciences, October 1, 2007; 14(7): 629 - 645. [Abstract] [PDF]

				M. Sugimoto, S. Yoshida, S. Kennedy, M. Deguchi, N. Ohara, and T. Maruo Matrix Metalloproteinase-1 and -9 Promoter Polymorphisms and Endometrial Carcinoma Risk in a Japanese Population Reproductive Sciences, October 1, 2006; 13(7): 523 - 529. [Abstract] [PDF]

				R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]

				Y. Zhou, C. Yu, X. Miao, Y. Wang, W. Tan, T. Sun, X. Zhang, P. Xiong, and D. Lin Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility Carcinogenesis, June 1, 2005; 26(6): 1117 - 1121. [Abstract] [Full Text] [PDF]

				M. R. Spitz, X. Wu, and G. Mills Integrative Epidemiology: From Risk Assessment to Outcome Prediction J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275. [Abstract] [Full Text] [PDF]

				J. Zhang, X. Jin, S. Fang, Y. Li, R. Wang, W. Guo, N. Wang, Y. Wang, D. Wen, L. Wei, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma Carcinogenesis, December 1, 2004; 25(12): 2519 - 2524. [Abstract] [Full Text] [PDF]

				X. Miao, T. Sun, Y. Wang, X. Zhang, W. Tan, and D. Lin Functional STK15 Phe31Ile Polymorphism Is Associated with the Occurrence and Advanced Disease Status of Esophageal Squamous Cell Carcinoma Cancer Res., April 15, 2004; 64(8): 2680 - 2683. [Abstract] [Full Text] [PDF]

				Y. Zhou, C. Yu, X. Miao, W. Tan, G. Liang, P. Xiong, T. Sun, and D. Lin Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes Carcinogenesis, March 1, 2004; 25(3): 399 - 404. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miao, X. Articles by Lin, D. Search for Related Content PubMed PubMed Citation Articles by Miao, X. Articles by Lin, D.